Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: Influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity

British Journal of Cancer

Volumn 104, Issue 4, 2011, Pages 605-612

  Kim, K P ^a   Jang, G ^a   Hong, Y S ^a   Lim, H S ^a   Bae, K S ^a   Kim, H S ^b   Lee, S S ^b   Shin, J G ^b   Lee, J L ^a   Ryu, M H ^a   Chang, H M ^a   Kang, Y K ^a   Kim, T W ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

CRPC; dexamethasone; diethylstilbestrol; treatment sequencing

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CYTOCHROME P450 2A6; OXALIPLATIN;

ADULT; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BILE DUCT CANCER; BILE DUCT CARCINOMA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DNA POLYMORPHISM; DRUG EFFICACY; DRUG SAFETY; DRUG TRANSFORMATION; FEBRILE NEUTROPENIA; FEMALE; GALLBLADDER CANCER; GENOTYPE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARYL HYDROCARBON HYDROXYLASES; BILIARY TRACT NEOPLASMS; BIOMARKERS, PHARMACOLOGICAL; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; METABOLIC DETOXICATION, DRUG; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; OXONIC ACID; POLYMORPHISM, SINGLE NUCLEOTIDE; TEGAFUR; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79951609864     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.17     Document Type: Article

References (42)

1. Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, Houghton M, Urrea P (2005) Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 23(28): 6957-6965
2. Choi CW, Choi IK, Seo JH, Kim BS, Kim JS, Kim CD, Um SH, Kim YH (2000) Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol 23(4): 425-428 (Pubitemid 32429160)
3. Chu QS, Hammond LA, Schwartz G, Ochoa L, Rha SY, Denis L, Molpus K, Roedig B, Letrent SP, Damle B, DeCillis AP, Rowinsky EK (2004) Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28- day schedule in patients with advanced malignancies. Clin Cancer Res 10(15): 4913-4921 (Pubitemid 39099764)
4. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1): 31-41
5. Cohen SJ, Leichman CG, Yeslow G, Beard M, Proefrock A, Roedig B, Damle B, Letrent SP, DeCillis AP, Meropol NJ (2002) Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer. Clin Cancer Res 8(7): 2116-2122 (Pubitemid 34753581)
6. Ducreux M, Rougier P, Fandi A, Clavero-Fabri MC, Villing AL, Fassone F, Fandi L, Zarba J, Armand JP (1998) Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol 9(6): 653-656 (Pubitemid 28318199)
7. Eckel F, Schmid RM (2007) Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 96(6): 896-902 (Pubitemid 46452283)
8. Fujita K, Yamamoto W, Endo S, Endo H, Nagashima F, Ichikawa W, Tanaka R, Miya T, Araki K, Kodama K, Sunakawa Y, Narabayashi M, Miwa K, Ando Y, Akiyama Y, Kawara K, Kamataki T, Sasaki Y (2008) CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1. Cancer Sci 99(5): 1049-1054 (Pubitemid 351997611)
9. Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D, Dorval E, Piot G, Morel A, Boisdron-Celle M (2008) Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 26(13): 2099-2105
10. Goh BC, Soo RA, Lim S, Zhang J, Furuie T, Urrea PD, Rosen LS (2008) Inter-ethnic variability of S-1 pharmacokinetics (PK) and correlation with CYP2A6 phenotyping. J Clin Oncol ASCO Annu Meet Proc 26: (abstract 2507)
11. Gusella M, Crepaldi G, Barile C, Bononi A, Menon D, Toso S, Scapoli D, Stievano L, Ferrazzi E, Grigoletto F, Ferrari M, Padrini R (2006) Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients onadjuvanttherapyforcolorectal cancer. Ann Oncol 17(11): 1656-1660 (Pubitemid 44680886)
12. Hezel AF, Zhu AX (2008) Systemic therapy for biliary tract cancers. Oncologist 13(4): 415-423 (Pubitemid 351679921)
13. Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, Nakano Y, Ishizuka H, Yamada Y, Uno S, Taguchi T, Shirasaka T (1999) Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 5(8): 2000-2005 (Pubitemid 29399250)
14. Hoff PM, Saad ED, Ajani JA, Lassere Y, Wenske C, Medgyesy D, Dwivedy S, Russo M, Pazdur R (2003) Phase I study with pharmacokinetics ofS-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res 9(1): 134-142 (Pubitemid 36109725)
15. Ichikawa W, Takahashi T, Suto K, Yamashita T, Nihei Z, Shirota Y, Shimizu M, Sasaki Y, Hirayama R (2004) Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer 91(7): 1245-1250 (Pubitemid 39424782)
16. Ikeda K, Yoshisue K, Matsushima E, Nagayama S, Kobayashi K, Tyson CA, Chiba K, Kawaguchi Y (2000) Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. Clin Cancer Res 6(11): 4409-4415
17. Ikeda M, Okusaka T, Ueno H, Morizane C, Furuse J, Ishii H (2005) A phase II trial of Uracil-tegafur (UFT) in patients with advanced biliary tract carcinoma. Jpn J Clin Oncol 35(8): 439-443 (Pubitemid 41309196)
18. Kaida Y, Inui N, Suda T, Nakamura H, Watanabe H, Chida K (2008) The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer. Clin Pharmacol Ther 83(4): 589-594 (Pubitemid 351417063)
19. Kang M, Lee J, Kim T, Lee S, Park D, Seo D, Kim M (2010) Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in advanced biliary tract adenocarcinoma. J Clin Oncol 28(15s): abstr 4029
20. Kim HS, Park MJ, Uhm JE, Lee Y, Lee HY, Kang EM, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS (2009) A phase I trial of S-1 with oxaliplatin in patients with relapsed and metastatic colorectal cancer. Int J Colorectal Dis 24(11): 1311-1316
21. Kim MJ, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ (2008a) Gemcitabine-based versus fluoropyrimidine-based chemo-therapy with or without platinum in unresectable biliary tract cancer: a retrospective study. BMC Cancer 8: 374
22. Kim TW, Chang HM, Kang HJ, Lee JR, Ryu MH, Ahn JH, Kim JH, Lee JS, Kang YK (2003) Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol 14(7): 1115-1120 (Pubitemid 36950177)
23. Kim YJ, Im SA, Kim HG, Oh SY, Lee KW, Choi IS, Oh DY, Lee SH, Kim JH, Kim DW, Kim TY, Kim SW, Heo DS, Yoon YB, Bang YJ (2008b) A phase II trial ofS-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer. Ann Oncol 19(1): 99-103
24. Kong SY, Lim HS, Nam BH, Kook MC, Kim YW, Ryu KW, Lee JH, Choi IJ, Lee JS, Park YI, Kim NK, Park SR (2009) Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer. Pharmacogenomics 10(7): 1147-1155
25. Machin C, Campbell M, Fayers P, Pinol A (1997) Sample Size Tables for Clinical Studies 2nd edn. Blackwell Science: Oxford and London, UK
26. Mwenifumbo JC, Sellers EM, Tyndale RF (2007) Nicotine metabolism and CYP2A6 activity in a population of black African descent: impact of gender and light smoking. Drug Alcohol Depend 89(1): 24-33 (Pubitemid 46602868)
27. Nakajima M, Fukami T, Yamanaka H, Higashi E, Sakai H, Yoshida R, Kwon JT, McLeod HL, Yokoi T (2006) Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther 80(3): 282-297 (Pubitemid 44313906)
28. Nakajima M, Kwon JT, Tanaka N, Zenta T, Yamamoto Y, Yamamoto H, Yamazaki H, Yamamoto T, Kuroiwa Y, Yokoi T (2001) Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin Pharmacol Ther 69(1): 72-78 (Pubitemid 32108674)
29. Nehls O, Oettle H, Hartmann JT, Hofheinz RD, Hass HG, Horger MS, Koppenhofer U, Hochhaus A, Stieler J, Trojan J, Gregor M, Klump B (2008) Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 98(2): 309-315 (Pubitemid 351161262)
30. Oh SY, Lee GW, Kim HG, Kim TH, Kim HJ, Kang JH (2008) Phase II trial of S-1 in combination with oxaliplatin in previously untreated patients with recurrent or inoperable biliary tract cancer. Chemotherapy 54(6): 479-484
31. Park I, Lee JL, Ryu MH, Kim TW, Chang HM, Lee SS, Sohn BS, Kim EK, Park do H, Suh DW, Lee SK, Kim MH, Lee J (2009) Efficacy and safety of S-1 monotherapy in patients with advanced biliary tract adenocarcino-ma: retrospective analysis of 162 patients. Oncology 76(2): 126-132
32. Park KH, Choi IK, Kim SJ, Oh SC, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS (2005) The efficacy of epirubicin, cisplatin, uracil/tegafur, and leucovorin in patients with advanced biliary tract carcinoma. Cancer 103(11): 2338-2343
33. Peters GJ, Noordhuis P, Van Kuilenburg AB, Schornagel JH, Gall H, Turner SL, Swart MS, Voorn D, Van Gennip AH, Wanders J, Holwerda U, Smid K, Giaccone G, Fumoleau P, Van Groeningen CJ (2003) Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. Cancer Chemother Pharmacol 52(1): 1-12 (Pubitemid 36920622)
34. Sasaki T, Isayama H, Yashima Y, Yagioka H, Kogure H, Arizumi T, Togawa O, Matsubara S, Ito Y, Nakai Y, Sasahira N, Hirano K, Tsujino T, Tada M, Kawabe T, Omata M (2009) S-1 monotherapy in patients with advanced biliary tract cancer. Oncology 77(1): 71-74
35. Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF (2004) Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 14(9): 615-626 (Pubitemid 39281816)
36. Sharma A, Dwary AD, Mohanti BK, Deo SV, Pal S, Sreenivas V, Raina V, Shukla NK, Thulkar S, Garg P, Chaudhary SP (2010) Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol 28(30): 4581-4586
37. Shirasaka T, Shimamoto Y, Fukushima M (1993) Inhibition by oxonic acid ofgastrointestinal toxicity of5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53(17): 4004-4009 (Pubitemid 23267702)
38. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3): 205-216
39. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14): 1273-1281
40. Verslype C, Prenen H, Van Cutsem E (2008) The role of chemotherapy in biliary tract carcinoma. HPB (Oxford) 10(3): 164-167 (Pubitemid 352016240)
41. Yamada Y, Tahara M, Miya T, Satoh T, Shirao K, Shimada Y, Ohtsu A, Sasaki Y, Tanigawara Y (2008) Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer. Br J Cancer 98(6): 1034-1038 (Pubitemid 351399808)
42. Zang DY, Lee BH, Park HC, Song HH, Kim HJ, Jung JY, Kim JH, Kim HY, Kwon JH, Hwang SW, Park SR, Park CH, Kim KO, Kim MJ, Jang KM (2009) Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer. Ann Oncol 20(5): 892-896